SuperworthMcKesson Corporation MCK
Medical - Distribution, Healthcare
$910.33
−1.23%
- Market cap
- $106.1B
- PE
- 24.4×
- 10y median 25.1×
- Forward PE
- Price to sales
- 0.3×
- EV/EBIT
- 16.4×
- Revenue, 12 months
- $411B
- +9% on a year ago
- Net margin
- 1.1%
- Free cash flow yield
- 5.8%
McKesson trades at 24.4× trailing earnings, near its ten-year median. Revenue was $411B over the last twelve months, up 9% on a year earlier with a 1% net margin.
Charts
Financials
| Income statement | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $80.9B | $76.4B | $79.3B | $93.7B | $95.3B+18% | $90.8B+19% | $97.8B+23% | $103.2B+10% | $106.2B+11% | $96.3B+6% | $105.4B+8% | |
| Cost of revenue | $77.7B | $72.8B | $76.1B | $90.4B | $92B+18% | $87.2B+20% | $94.5B+24% | $99.6B+10% | $102.5B+11% | $92.3B+6% | $101.7B+8% |
| Gross profit | $3.2B | $3.6B | $3.2B | $3.2B | $3.3B+4% | $3.6B+2% | $3.3B+4% | $3.5B+9% | $3.7B+12% | $4B+11% | $3.7B+12% |
| SG&A | $2.5B | $2.2B | $2B | $2.5B | $2B−19% | $2B−10% | $2.2B+10% | $2.1B−17% | $2B+0% | $1.8B−9% | $2.3B+3% |
| $642M | $1.2B | $1B | $578M | $1.2B+91% | $1.6B+31% | $1B+1% | $1.4B+143% | $1.6B+32% | $2.1B+35% | $1.3B+27% | |
| Interest expense | $64M | $80M | $66M | $78M | $67M+5% | $45M−44% | $49M−26% | $74M−5% | $63M−6% | −$61M | $77M+57% |
| Pre-tax income | $612M | $1.2B | $1.1B | $534M | $1.2B+100% | $1.5B+30% | $1.1B−3% | $1.4B+161% | $1.6B+33% | $2.1B+40% | $1.3B+25% |
| −$18M | $340M | $124M | $247M | $298M | $209M−39% | $220M+77% | $232M−6% | $380M+28% | $270M+29% | $276M+26% | |
| Net income | $589M | $791M | $915M | $241M | $879M+49% | $1.3B+59% | $784M−14% | $1.1B+361% | $1.2B+35% | $1.7B+34% | $614M−22% |
| $4.42 | $6.01 | $7.00 | $1.87 | $6.95+57% | $10.01+67% | $6.25−11% | $8.92+377% | $9.59+38% | $13.71+37% | $5.15−18% | |
| 133.3M | 131.6M | 130.7M | 129.3M | 126.6M−5% | 125.9M−4% | 125.5M−4% | 124.4M−4% | 123.7M−2% | 122.7M−3% | 119.2M−5% |
From each company's 10-Q and 10-K filings. Fiscal years are four fiscal quarters added up; balance sheet lines are as of the period's end. Growth is on the same period a year earlier.
Estimates
Next earnings report: .
Analyst consensus for the next eight quarters, with the range from the lowest to the highest estimate, is part of Superworth Pro.
Peers
Companies in Healthcare within ten times McKesson's size, closest in size first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| MCKMcKesson Corporation | $106.1B | 24.4× | 25.1× | 0.3× | +9% | 1.1% | |
| SYKStryker Corporation | $105.6B | 28.5× | 41.2× | 4.1× | +8% | 14.4% | |
| MDTMedtronic plc | $109.4B | 21.1× | 28.4× | 2.9× | +10% | 13.9% | |
| CVSCVS Health Corp. | $112.5B | 23.3× | 16.2× | 0.3× | +7% | 1.2% | |
| HCAHCA Healthcare, Inc. | $95.1B | 14.7× | 13.8× | 1.2× | +7% | 8.8% | |
| BMYBristol-Myers Squibb Company | $122B | 13.1× | 19.9× | 2.5× | +3% | 18.9% | |
| VRTXVertex Pharmaceuticals Incorporated | $128.2B | 29.4× | 28.4× | 10.2× | +10% | 35.0% | |
| ELVElevance Health Inc. | $87.7B | 18.0× | 17.6× | 0.4× | +6% | 2.5% | |
| ISRGIntuitive Surgical, Inc. | $146.4B | 47.5× | 69.0× | 13.3× | +21% | 28.4% | |
| REGNRegeneron Pharmaceuticals, Inc. | $76.4B | 18.3× | 19.8× | 4.9× | +9% | 27.9% | |
| CICigna Corporation | $73.6B | 11.5× | 16.1× | 0.3× | +8% | 2.3% | |
| Peer median | $107.5B | 19.7× | 19.8× | 2.7× | +8% | 14.2% |
About
- Industry
- Medical - Distribution
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .